397 related articles for article (PubMed ID: 30048367)
1. Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated?
Oikonomou D; Georgiopoulos G; Katsi V; Kourek C; Tsioufis C; Alexopoulou A; Koutli E; Tousoulis D
Eur J Gastroenterol Hepatol; 2018 Sep; 30(9):979-985. PubMed ID: 30048367
[TBL] [Abstract][Full Text] [Related]
2. Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment options.
Milic S; Mikolasevic I; Krznaric-Zrnic I; Stanic M; Poropat G; Stimac D; Vlahovic-Palcevski V; Orlic L
Drug Des Devel Ther; 2015; 9():4835-45. PubMed ID: 26316717
[TBL] [Abstract][Full Text] [Related]
3. Obesity and metabolic syndrome as risk factors for the development of non-alcoholic fatty liver disease as diagnosed by ultrasound.
Petrović G; Bjelaković G; Benedeto-Stojanov D; Nagorni A; Brzački V; Marković-Živković B
Vojnosanit Pregl; 2016 Oct; 73(10):910-20. PubMed ID: 29327896
[TBL] [Abstract][Full Text] [Related]
4. Is Nonalcoholic Fatty Liver Disease Indeed the Hepatic Manifestation of Metabolic Syndrome?
Katsiki N; Perez-Martinez P; Anagnostis P; Mikhailidis DP; Karagiannis A
Curr Vasc Pharmacol; 2018; 16(3):219-227. PubMed ID: 28669328
[TBL] [Abstract][Full Text] [Related]
5. Renin-angiotensin system and fibrosis in non-alcoholic fatty liver disease.
Goh GB; Pagadala MR; Dasarathy J; Unalp-Arida A; Sargent R; Hawkins C; Sourianarayanane A; Khiyami A; Yerian L; Pai R; McCullough AJ; Dasarathy S
Liver Int; 2015 Mar; 35(3):979-85. PubMed ID: 24905085
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
7. Prevalence, risk factors, and predictors of nonalcoholic fatty liver disease among schoolchildren: a hospital-based study in Alexandria, Egypt.
Alkassabany YM; Farghaly AG; El-Ghitany EM
Arab J Gastroenterol; 2014 Jun; 15(2):76-81. PubMed ID: 25097051
[TBL] [Abstract][Full Text] [Related]
8. Nonalcoholic fatty liver disease as a multi-systemic disease.
Fotbolcu H; Zorlu E
World J Gastroenterol; 2016 Apr; 22(16):4079-90. PubMed ID: 27122660
[TBL] [Abstract][Full Text] [Related]
9. Hypertension: renin-angiotensin-aldosterone system alterations.
Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
[TBL] [Abstract][Full Text] [Related]
10. Nonalcoholic fatty liver disease and the renin-angiotensin system blockers in the patients with chronic kidney disease.
Orlic L; Mikolasevic I; Lukenda V; Anic K; Jelic I; Racki S
Wien Klin Wochenschr; 2015 May; 127(9-10):355-62. PubMed ID: 25412597
[TBL] [Abstract][Full Text] [Related]
11. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
Yamagishi S; Takeuchi M
Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
[TBL] [Abstract][Full Text] [Related]
12. Renin-angiotensin system at the crossroad of hypertension and hypercholesterolemia.
Borghi C; Urso R; Cicero AF
Nutr Metab Cardiovasc Dis; 2017 Feb; 27(2):115-120. PubMed ID: 27745933
[TBL] [Abstract][Full Text] [Related]
13. Review article: drug-induced liver injury in the context of nonalcoholic fatty liver disease - a physiopathological and clinical integrated view.
Bessone F; Dirchwolf M; Rodil MA; Razori MV; Roma MG
Aliment Pharmacol Ther; 2018 Nov; 48(9):892-913. PubMed ID: 30194708
[TBL] [Abstract][Full Text] [Related]
14. Nonalcoholic Fatty Liver Disease and Advanced Fibrosis in US Adults Across Blood Pressure Categories.
Ciardullo S; Monti T; Sala I; Grassi G; Mancia G; Perseghin G
Hypertension; 2020 Aug; 76(2):562-568. PubMed ID: 32594797
[TBL] [Abstract][Full Text] [Related]
15. [Non-alcoholic fatty liver disease (NAFLD)].
Rau M; Weiss J; Geier A
Dtsch Med Wochenschr; 2015 Jul; 140(14):1051-5. PubMed ID: 26182253
[TBL] [Abstract][Full Text] [Related]
16. Complete inhibition of the renin-angiotensin-aldosterone system; where do we stand?
Chen SS; Seliger SL; Fried LF
Curr Opin Nephrol Hypertens; 2014 Sep; 23(5):449-55. PubMed ID: 25014549
[TBL] [Abstract][Full Text] [Related]
17. The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?
Papademetriou M; Athyros VG; Geladari E; Doumas M; Tsioufis C; Papademetriou V
Curr Vasc Pharmacol; 2018; 16(3):254-268. PubMed ID: 28676027
[TBL] [Abstract][Full Text] [Related]
18. Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning?
Baran B; Akyüz F
World J Gastroenterol; 2014 Oct; 20(39):14219-29. PubMed ID: 25339808
[TBL] [Abstract][Full Text] [Related]
19. [Advances in diagnosis and treatment of nonalcoholic fatty liver disease].
Zhu C; Zhou D; Fan J
Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):81-4. PubMed ID: 26983471
[TBL] [Abstract][Full Text] [Related]
20. [Relation of risk factors between metabolic syndrome and nonalcoholic fatty liver disease in children and adolescents].
Smolka V; Ehrmann J; Tkachyk O; Zápalka M
Cas Lek Cesk; 2014; 153(2):91-7. PubMed ID: 24797780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
